Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).

Bispecific antibodies (BsAb) can be used to retarget T cells irrespective of their specificity to certain target cells inducing target cell lysis. We have tested the efficacy of the BsAb SHR-1, directed against the T cell antigen CD3 and the B cell antigen CD19 to induce (malignant) B cell kill by T...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Haagen, I A, van de Griend, R, Clark, M, Geerars, A, Bast, B, de Gast, B
Médium: Artigo
Jazyk:Inglês
Vydáno: 1992
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1554560/
https://ncbi.nlm.nih.gov/pubmed/1281055
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky